Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1901
Harvard Bioscience
HBIO
$37.8M
| $3.2M | ﹤0.01% |
103,213
+35,530
| +52% | +$957K |
2013 Q2
28 quarters
|
|
|
OPI
1902
DELISTED
Office Properties Income Trust
OPI
| $3.2M | ﹤0.01% |
123,200
-211,600
| -63% | -$5.51M |
2019 Q3
3 quarters
|
|
1903
Archrock
AROC
$5.13B
| $3.19M | ﹤0.01% |
+492,128
| New | +$2.57M |
2020 Q2
0 quarters
|
|
1904
Asbury Automotive
ABG
$3.05B
| $3.19M | ﹤0.01% |
+41,200
| New | +$2.77M |
2020 Q2
0 quarters
|
|
|
GBT
1905
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.18M | ﹤0.01% |
50,400
+42,300
| +522% | +$2.9M |
2020 Q1
1 quarter
|
|
1906
Tredegar Corp
TG
$274M
| $3.18M | ﹤0.01% |
206,400
-21,300
| -9% | -$330K |
2018 Q2
8 quarters
|
|
1907
BancFirst
BANF
$3.63B
| $3.18M | ﹤0.01% |
78,300
-43,600
| -36% | -$1.6M |
2013 Q2
28 quarters
|
|
1908
Travelzoo
TZOO
$52M
| $3.18M | ﹤0.01% |
563,149
-57,700
| -9% | -$318K |
2013 Q2
28 quarters
|
|
1909
Westport Fuel Systems
WPRT
$34.6M
| $3.17M | ﹤0.01% |
255,575
-92,490
| -27% | -$1.03M |
2017 Q3
11 quarters
|
|
|
CVET
1910
DELISTED
Covetrus, Inc. Common Stock
CVET
| $3.15M | ﹤0.01% |
+175,900
| New | +$2.31M |
2020 Q2
0 quarters
|
|
1911
Axogen
AXGN
$2.09B
| $3.14M | ﹤0.01% |
339,807
+191,507
| +129% | +$1.72M |
2019 Q3
3 quarters
|
|
1912
AdaptHealth
AHCO
$852M
| $3.14M | ﹤0.01% |
194,900
+143,400
| +278% | +$2.4M |
2020 Q1
1 quarter
|
|
1913
Rimini Street
RMNI
$384M
| $3.14M | ﹤0.01% |
608,879
+167,100
| +38% | +$711K |
2018 Q3
7 quarters
|
|
1914
Korn Ferry
KFY
$4.09B
| $3.12M | ﹤0.01% |
+101,400
| New | +$2.9M |
2020 Q2
0 quarters
|
|
1915
DELISTED
CATALENT, INC.
CTLT
| $3.12M | ﹤0.01% |
+42,500
| New | +$2.89M |
2020 Q2
0 quarters
|
|
1916
Cushman & Wakefield Ltd
CWK
$2.73B
| $3.11M | ﹤0.01% |
+249,700
| New | +$2.81M |
2020 Q2
0 quarters
|
|
1917
Amdocs
DOX
$6.34B
| $3.11M | ﹤0.01% |
51,100
-225,300
| -82% | -$13.9M |
2013 Q2
28 quarters
|
|
|
BDSI
1918
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $3.1M | ﹤0.01% |
711,863
+33,463
| +5% | +$150K |
2019 Q1
5 quarters
|
|
1919
Arvinas
ARVN
$468M
| $3.1M | ﹤0.01% |
92,500
-127,995
| -58% | -$5.43M |
2019 Q4
2 quarters
|
|
1920
Kinder Morgan
KMI
$73.1B
| $3.09M | ﹤0.01% |
+203,431
| New | +$3.09M |
2020 Q2
0 quarters
|
|
1921
MasterCraft Boat Holdings
MCFT
$485M
| $3.08M | ﹤0.01% |
161,727
-396,372
| -71% | -$4.99M |
2016 Q2
16 quarters
|
|
1922
Coeur Mining
CDE
$15.8B
| $3.08M | ﹤0.01% |
605,628
-5,279,200
| -90% | -$24M |
2013 Q2
28 quarters
|
|
1923
AZZ Inc
AZZ
$3.92B
| $3.07M | ﹤0.01% |
+89,400
| New | +$2.73M |
2020 Q2
0 quarters
|
|
1924
CervoMed
CRVO
$34M
| $3.07M | ﹤0.01% |
41,957
+19,568
| +87% | +$1.19M |
2017 Q4
10 quarters
|
|
1925
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
| $3.07M | ﹤0.01% |
452,200
-2,362,420
| -84% | -$12.4M |
2015 Q3
19 quarters
|
|
Similar funds
Renaissance Technologies's Q2 2020 Portfolio in Review
As of Q2 2020, Renaissance Technologies held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Renaissance Technologies withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,365 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Renaissance Technologies opened a new position in Uber worth $187M.
- Renaissance Technologies's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Renaissance Technologies added most to Zoom in Q2 2020, an estimated $806M increase.
- Renaissance Technologies's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Renaissance Technologies fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Renaissance Technologies's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Renaissance Technologies opened 583 new positions and closed 596 in Q2 2020.
- Renaissance Technologies's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.